Alexandra Legge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra Legge has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Claire E. H. Barber
Department of Community Health Sciences Cumming School of Medicine, University of Calgary Calgary Alberta Canada
5 shared publications - Arnav Agarwal
University of Alberta
3 shared publications - Cheryl Barnabe
Cumming School of Medicine, University of Calgary
3 shared publications - Dawn P. Richards
Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada
3 shared publications - Glen Stewart Hazlewood
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, University of British Columbia, Vancouver, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada
3 shared publications - J. Carter Thorne
J.C. Thorne, MD, FRCPC, Assistant Past Professor, Department of Medicine, University of Toronto; Medical Director, The Arthritis Program; Board Chair Centre of Arthritis Excellence, Newmarket, Ontario, Canada
3 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002282
The lupus damage index revision program: Results from the item generation and reduction phases
Objective: A data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results for a revised SDI. Methods: Item generation included a literature review by literature review groups and a Delphi exercise of international systemic lupus erythematosus experts and patients. Item reduction involved Delphi rounds in which items with a median appropriateness score of ≤ 4 of 9 were excluded. A 14-member item reduction committee assessed remaining items and removed those that did not reflect the damage construct, were rare, or were not feasible to assess. The clinical domain groups then refined the remaining items and their definitions. Results: The Delphi panel included 146 individuals from 35 countries. The Delphi exercise nominated 2256 items, and the literature review identified 117 items. After removing redundancies, 226 candidate items remained. Subsequent Delphi rounds, followed by review by the item reduction committee and clinical domain groups, resulted in 39 items across 13 domains. Eleven items from the original SDI, including proteinuria and cranial neuropathy, were removed and several new items were proposed, including growth failure/reduced final height and adrenal insufficiency. Severity-based subitems are proposed for 17 items (43.6%). Conclusion: This data-driven and expert/patient consensus-based process has proposed 39 candidate items, some with subitems, and definitions for a revised SDI. Weighting of items and subitems is underway to develop a clinical scoring system.
- 12 August 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002282
Open AccessThe lupus damage index revision program: Results from the item generation and reduction phases
Objective: A data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results for a revised SDI. Methods: Item generation included a literature review by literature review groups and a Delphi exercise of international systemic lupus erythematosus experts and patients. Item reduction involved Delphi rounds in which items with a median appropriateness score of ≤ 4 of 9 were excluded. A 14-member item reduction committee assessed remaining items and removed those that did not reflect the damage construct, were rare, or were not feasible to assess. The clinical domain groups then refined the remaining items and their definitions. Results: The Delphi panel included 146 individuals from 35 countries. The Delphi exercise nominated 2256 items, and the literature review identified 117 items. After removing redundancies, 226 candidate items remained. Subsequent Delphi rounds, followed by review by the item reduction committee and clinical domain groups, resulted in 39 items across 13 domains. Eleven items from the original SDI, including proteinuria and cranial neuropathy, were removed and several new items were proposed, including growth failure/reduced final height and adrenal insufficiency. Severity-based subitems are proposed for 17 items (43.6%). Conclusion: This data-driven and expert/patient consensus-based process has proposed 39 candidate items, some with subitems, and definitions for a revised SDI. Weighting of items and subitems is underway to develop a clinical scoring system.
- Open Access
- 27 May 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (3) , 100827
Frailty is associated with lower-limb osteoarthritis incidence over six-years regardless of sex and type of frailty index in the Canadian longitudinal study on aging
- 27 May 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (3) , 100827
Open AccessFrailty is associated with lower-limb osteoarthritis incidence over six-years regardless of sex and type of frailty index in the Canadian longitudinal study on aging
- Open Access
- 14 May 2026
- Published by Wiley in Arthritis & Rheumatology
Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine
Objective: To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)–exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort. Methods: LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru, and Mexico. Pregnant women with SLE are enrolled before 17 weeks and followed in the second (20–24 weeks) and third (30–34 weeks) trimesters and postpartum (8–12 weeks). Because ICP occurs after 20 weeks, only pregnancies with a second‐trimester visit were included. Follow‐up began at that visit and continued until delivery. AZA exposure was modeled as time varying. The primary outcome was iatrogenic delivery for ICP or spontaneous preterm birth occurring after ICP diagnosis. Multivariable Cox models with frailties adjusted for relevant covariates. At the Montreal site, thiopurine metabolites and shunting were assessed. Results: Among 127 SLE pregnancies (46 AZA exposed, 81 unexposed), 10 ICP cases occurred (each in a distinct woman): 8 among AZA exposed (17.4%, 95% confidence interval [CI] 9.1–30.7) and 2 among unexposed (2.5%, 95% CI 0.7–8.6). AZA exposure was associated with a substantially increased risk of ICP (adjusted hazard ratio 12.1, 95% CI 2.4–59.7). All ICP cases with metabolite data (4 of 4) showed second‐trimester shunting. Among all pregnancies with second‐trimester metabolite data (n = 22), 36.4% (95% CI 19.7–57.0) were shunting, and 50.0% (95% CI 21.5–78.5) of these developed ICP. Conclusion: We observed that AZA exposure may be strongly associated with ICP in SLE pregnancies. Second‐trimester thiopurine shunting may identify women at high risk, supporting the value of metabolite monitoring.
- 14 May 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessIncreased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine
Objective: To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)–exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort. Methods: LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru, and Mexico. Pregnant women with SLE are enrolled before 17 weeks and followed in the second (20–24 weeks) and third (30–34 weeks) trimesters and postpartum (8–12 weeks). Because ICP occurs after 20 weeks, only pregnancies with a second‐trimester visit were included. Follow‐up began at that visit and continued until delivery. AZA exposure was modeled as time varying. The primary outcome was iatrogenic delivery for ICP or spontaneous preterm birth occurring after ICP diagnosis. Multivariable Cox models with frailties adjusted for relevant covariates. At the Montreal site, thiopurine metabolites and shunting were assessed. Results: Among 127 SLE pregnancies (46 AZA exposed, 81 unexposed), 10 ICP cases occurred (each in a distinct woman): 8 among AZA exposed (17.4%, 95% confidence interval [CI] 9.1–30.7) and 2 among unexposed (2.5%, 95% CI 0.7–8.6). AZA exposure was associated with a substantially increased risk of ICP (adjusted hazard ratio 12.1, 95% CI 2.4–59.7). All ICP cases with metabolite data (4 of 4) showed second‐trimester shunting. Among all pregnancies with second‐trimester metabolite data (n = 22), 36.4% (95% CI 19.7–57.0) were shunting, and 50.0% (95% CI 21.5–78.5) of these developed ICP. Conclusion: We observed that AZA exposure may be strongly associated with ICP in SLE pregnancies. Second‐trimester thiopurine shunting may identify women at high risk, supporting the value of metabolite monitoring.
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1)
Development and validation of a clinical risk prediction rule to identify inflammatory arthritis at the point of rheumatology triage
Objectives: To develop and validate a clinical prediction rule to identify inflammatory arthritis (IA) using routinely collected triage data, without ACPA. Methods: Prospective observational data from 184 patients referred to a tertiary care rheumatology clinic for joint pain over a 9-month period and meeting inclusion criteria were used to derive a clinical risk prediction rule for the diagnosis of IA versus non-IA, utilizing penalized and stepwise logistic regression modelling, including age, sex, CRP and RF. Internal validation was performed using 5-fold cross-validation. A population within the UK Biobank with a diagnosis of incident IA or non-IA, within 180 days of baseline assessment (N = 2828), was used for broad external domain validation. Model performance was assessed by the c-statistic (cvAUC) and the Hosmer–Lemeshow test. Results: In the derivation cohort, CRP had the strongest association with diagnosis of IA in both models, other important predictors being sex and CRP twice the upper limit of normal in the stepwise model (cvAUC = 0.72, 95% CI 0.58, 0.85) and additionally RF and age in the penalized regression model (cvAUC = 0.77, 95% CI 0.59, 0.95). When applied in the UK Biobank, AUC values decreased (0.54–0.55); however, limitations in accurately defining the timing of incident arthritis indicate the need for geographical validation in a cohort that better fits the target population and setting. Conclusions: This simple prediction rule, utilizing demographic and laboratory data, performed well in discriminating IA from non-IA in the derivation population. Additional validation studies in similar clinical settings are required to further refine the model and determine generalizability.
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1)
Open AccessDevelopment and validation of a clinical risk prediction rule to identify inflammatory arthritis at the point of rheumatology triage
Objectives: To develop and validate a clinical prediction rule to identify inflammatory arthritis (IA) using routinely collected triage data, without ACPA. Methods: Prospective observational data from 184 patients referred to a tertiary care rheumatology clinic for joint pain over a 9-month period and meeting inclusion criteria were used to derive a clinical risk prediction rule for the diagnosis of IA versus non-IA, utilizing penalized and stepwise logistic regression modelling, including age, sex, CRP and RF. Internal validation was performed using 5-fold cross-validation. A population within the UK Biobank with a diagnosis of incident IA or non-IA, within 180 days of baseline assessment (N = 2828), was used for broad external domain validation. Model performance was assessed by the c-statistic (cvAUC) and the Hosmer–Lemeshow test. Results: In the derivation cohort, CRP had the strongest association with diagnosis of IA in both models, other important predictors being sex and CRP twice the upper limit of normal in the stepwise model (cvAUC = 0.72, 95% CI 0.58, 0.85) and additionally RF and age in the penalized regression model (cvAUC = 0.77, 95% CI 0.59, 0.95). When applied in the UK Biobank, AUC values decreased (0.54–0.55); however, limitations in accurately defining the timing of incident arthritis indicate the need for geographical validation in a cohort that better fits the target population and setting. Conclusions: This simple prediction rule, utilizing demographic and laboratory data, performed well in discriminating IA from non-IA in the derivation population. Additional validation studies in similar clinical settings are required to further refine the model and determine generalizability.
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (3) , 314-321
Association of Frailty With Risk of Osteoarthritis Development, Progression, and Worse Clinical Outcomes in Older Adults
Objective: Both frailty and osteoarthritis (OA) become common with aging. Given their shared age-related incidence, we hypothesized that greater baseline frailty—measured by a frailty index—would be associated with worse OA outcomes, including higher incidence, poorer Knee Injury and Osteoarthritis Outcome Score (KOOS) trajectories, increased fall risk, and higher rates of total or partial knee arthroplasty (KA) or hip arthroplasty (HA) in middle-aged and older adults. Methods: A frailty index score was calculated for 4753 participants (58.53% female; mean age 61.2 years, 95% CI 60.94-61.46) from the Osteoarthritis Initiative (OAI), broken into control, incidence, and progression groups. Longitudinal OAI outcomes including incidence, KOOS progression, falls, and KA/HA were extracted for ~9 years from baseline. Results: Higher baseline frailty was associated with development of OA by 3-, 5-, and 9-year follow-up (all P < 0.001), with the greatest effect at 9 years (odds ratio [OR] 1.73, 95% CI 1.52-1.97, P < 0.001). Disease trajectory, as measured by KOOS subscale scores, was negatively influenced by increasing frailty (all P < 0.001), the greatest effect being on KOOS Function (estimate −9.52, 95% CI −10.28 to −8.77, P < 0.001). A 0.1 difference in baseline frailty index scores was associated with an increase in the odds of experiencing a fall within 3 years of baseline (OR 1.44, 95% CI 1.32-1.58, P < 0.001). Regardless of surgical site, frailty index scores did not significantly affect risk of experiencing KA/HA except in female participants undergoing HA (hazard ratio 1.29, 95% CI 1.04-1.61, P = 0.02). Conclusion: Frailty was associated with greater risk of OA incidence and falls, as well as KOOS-measured disease progression, but not joint replacement surgery-free time.
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (3) , 314-321
Association of Frailty With Risk of Osteoarthritis Development, Progression, and Worse Clinical Outcomes in Older Adults
Objective: Both frailty and osteoarthritis (OA) become common with aging. Given their shared age-related incidence, we hypothesized that greater baseline frailty—measured by a frailty index—would be associated with worse OA outcomes, including higher incidence, poorer Knee Injury and Osteoarthritis Outcome Score (KOOS) trajectories, increased fall risk, and higher rates of total or partial knee arthroplasty (KA) or hip arthroplasty (HA) in middle-aged and older adults. Methods: A frailty index score was calculated for 4753 participants (58.53% female; mean age 61.2 years, 95% CI 60.94-61.46) from the Osteoarthritis Initiative (OAI), broken into control, incidence, and progression groups. Longitudinal OAI outcomes including incidence, KOOS progression, falls, and KA/HA were extracted for ~9 years from baseline. Results: Higher baseline frailty was associated with development of OA by 3-, 5-, and 9-year follow-up (all P < 0.001), with the greatest effect at 9 years (odds ratio [OR] 1.73, 95% CI 1.52-1.97, P < 0.001). Disease trajectory, as measured by KOOS subscale scores, was negatively influenced by increasing frailty (all P < 0.001), the greatest effect being on KOOS Function (estimate −9.52, 95% CI −10.28 to −8.77, P < 0.001). A 0.1 difference in baseline frailty index scores was associated with an increase in the odds of experiencing a fall within 3 years of baseline (OR 1.44, 95% CI 1.32-1.58, P < 0.001). Regardless of surgical site, frailty index scores did not significantly affect risk of experiencing KA/HA except in female participants undergoing HA (hazard ratio 1.29, 95% CI 1.04-1.61, P = 0.02). Conclusion: Frailty was associated with greater risk of OA incidence and falls, as well as KOOS-measured disease progression, but not joint replacement surgery-free time.
- Open Access
- 1 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (3) , 701-702
Delayed onset vacuoles in a confirmed case of VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome
- 1 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (3) , 701-702
Open AccessDelayed onset vacuoles in a confirmed case of VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome
- Open Access
- 3 March 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (1) , e001452
Meeting report: The Systemic Lupus International Collaborating Clinics (SLICC) World Lupus Seminar on Africa
The Systemic Lupus International Collaborating Clinics (SLICC) is an international research group dedicated to promoting collaboration among scientific investigators in the study of systemic lupus erythematosus (SLE). Currently, most SLICC members are based in North America and Europe, with limited representation from other regions. SLICC recognises the importance of expanding its global collaborations and representation to ensure that its research accurately reflects the global burden of SLE and provides equal benefit to all patients with SLE worldwide. Given that SLICC currently lacks representation from the African continent, an opportunity was identified to convene a meeting bringing together lupus physicians with experience providing clinical care and conducting lupus research in Africa, along with members of the SLICC group. The purpose of the meeting was to share information regarding SLE in Africa, to discuss recent innovations and current challenges in the region and to explore future collaborations between SLICC members and colleagues in Africa in the areas of SLE clinical care, research and education. This meeting report highlights information presented during the seminar as well as a discussion of next steps moving forward.
- 3 March 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (1) , e001452
Open AccessMeeting report: The Systemic Lupus International Collaborating Clinics (SLICC) World Lupus Seminar on Africa
The Systemic Lupus International Collaborating Clinics (SLICC) is an international research group dedicated to promoting collaboration among scientific investigators in the study of systemic lupus erythematosus (SLE). Currently, most SLICC members are based in North America and Europe, with limited representation from other regions. SLICC recognises the importance of expanding its global collaborations and representation to ensure that its research accurately reflects the global burden of SLE and provides equal benefit to all patients with SLE worldwide. Given that SLICC currently lacks representation from the African continent, an opportunity was identified to convene a meeting bringing together lupus physicians with experience providing clinical care and conducting lupus research in Africa, along with members of the SLICC group. The purpose of the meeting was to share information regarding SLE in Africa, to discuss recent innovations and current challenges in the region and to explore future collaborations between SLICC members and colleagues in Africa in the areas of SLE clinical care, research and education. This meeting report highlights information presented during the seminar as well as a discussion of next steps moving forward.
- Open Access
- 1 February 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
TREX1-Associated Familial Chilblain Lupus With Cerebral Aneurysms Treated With Janus Kinase Inhibition
Familial chilblain lupus (FCL) is a rare monogenic interferonopathy associated with multiple genetic mutations, including TREX1, characterized by painful, bluish-red skin lesions on acral areas, typically after cold exposure.1-3 Associated symptoms include inflammatory arthritis, cytopenias, antinuclear antibody (ANA) positivity, and rarely, cerebral aneurysms.4,5
- 1 February 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Open AccessTREX1-Associated Familial Chilblain Lupus With Cerebral Aneurysms Treated With Janus Kinase Inhibition
Familial chilblain lupus (FCL) is a rare monogenic interferonopathy associated with multiple genetic mutations, including TREX1, characterized by painful, bluish-red skin lesions on acral areas, typically after cold exposure.1-3 Associated symptoms include inflammatory arthritis, cytopenias, antinuclear antibody (ANA) positivity, and rarely, cerebral aneurysms.4,5
- Open Access
- 15 December 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Dr. Roberts et al reply
We thank Dr. Steiman and colleagues1 for their interest and correspondence regarding our recent publication exploring the feasibility of physiotherapy-led rheumatology triage using a standardized triage algorithm.2 The algorithm used in this study relied on the referring providers9 physical examination, laboratory results, and radiographic results, as well as patient-reported questionnaire scores.
- 15 December 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Open AccessDr. Roberts et al reply
We thank Dr. Steiman and colleagues1 for their interest and correspondence regarding our recent publication exploring the feasibility of physiotherapy-led rheumatology triage using a standardized triage algorithm.2 The algorithm used in this study relied on the referring providers9 physical examination, laboratory results, and radiographic results, as well as patient-reported questionnaire scores.